Lowering blood pressure early during acute stroke did nothing to improve outcomes and may actually impair patients' ability to live independently later on, researchers affirmed in a randomized trial.
Candesartan (Atacand) started within 30 hours of stroke onset and given over seven days did not affect the combined six-month rate of death from vascular causes, myocardial infarction, or stroke compared with placebo (11.7% versus 11.3%, adjusted hazard ratio 1.09, P=0.52), Eivind Berge, MD, of Oslo University Hospital Ullevål, and colleagues found.
Functional disability was 17% more common with the drug (P=0.048), the group reported here at the American Stroke Association's International Stroke Conference and simultaneously online in The Lancet.
Full Article
No comments:
Post a Comment